EGFR and non-small cell lung carcinoma: Forty-seven participants with EGFR T790M mutation positive NSCLC with disease progression after first generation EGFR TKIs were enrolled between September 4, 2017 and June 11, 2019 and treated with induction osimertinib followed by an alternating regimen of gefitinib and osimertinib (Fig. 1a, b).